Literature DB >> 9196296

Induction therapy for clinical T4 oesophageal carcinoma; a plea for continued surgical exploration.

D Van Raemdonck1, E Van Cutsem, J Menten, N Ectors, W Coosemans, P De Leyn, T Lerut.   

Abstract

OBJECTIVE: Complete resection of a locally advanced oesophageal carcinoma is not always feasible when invading mediastinal structures. The use of induction therapy prior to surgical exploration in patients with these clinical T4 tumours is anticipated to improve the resectability rate.
METHODS: Patients, 18, who presented with a carcinoma of the thoracic oesophagus with clinical invasion into the carina (n = 6), trachea (n = 5), aorta (n = 4), lung (n = 2) and diaphragm (n = 1) were treated with concurrent chemotherapy and radiotherapy followed by surgical exploration. Follow-up was complete (mean of 17 +/- 3 months in all patients and 27 +/- 2 months in surviving patients).
RESULTS: All patients completed the induction therapy with acceptable toxicity and no mortality. Subjective improvement in dysphagia was substantial in 11 patients (in 8/11 patients (73%) however, there was still viable tumour in the resected specimen), it was minimal in six patients and absent in one patient. Objective response on imaging was complete in one patient, partial in eight patients and minimal in nine patients [in two of these nine patients (22%) nevertheless, the primary tumour had disappeared completely in the resected specimen (pT0)]. Resection was complete (R0) in 14 patients (78%) and incomplete (R1) in one patient (5%). Resection of the primary tumour was impossible (R2) in three patients (17%) because of macroscopic airway (n = 2) and hilar (n = 1) invasion on exploration. In these three patients the tumour was bypassed using a retrosternal split stomach. One patient was proven at the time of surgery to have a previously unidentified lung metastasis. In three patients (17%), no residual tumour cells were found in the resected oesophagus nor in the lymph nodes (pT0N0M0). There have been no in-hospital deaths. Actuarial 3 year survival was 43% in all patients, 55% in completely resected patients and 100% in sterilized patients (pT0N0M0). Median survival was 18 months in all patients.
CONCLUSIONS: Chemo/radiotherapy followed by surgery in patients with a clinical T4 oesophageal carcinoma is feasible with acceptable toxicity and no treatment-related mortality. Operability and resectability rate were high (100 and 83%, respectively) compared with historical controls. The primary tumour disappeared completely (pT0N0-1M0-1) in 28%. Tumour sterilization rate was 17%. Survival looks promising compared with historical controls. Subjective neither objective response following induction therapy clearly correlated with the final pTNM staging. This indicates that, in the absence of tumour progression, neither the patient nor the treating physician should jeopardize the chance for ultimate cure by denying surgical exploration following induction therapy.

Entities:  

Mesh:

Year:  1997        PMID: 9196296     DOI: 10.1016/s1010-7940(97)01194-9

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  7 in total

1.  Esophagectomy: is it necessary after chemoradiotherapy for a locally advanced T4 esophageal cancer? Prospective nonrandomized trial comparing chemoradiotherapy with surgery versus without surgery.

Authors:  Hiromasa Fujita; Susumu Sueyoshi; Toshiaki Tanaka; Yuichi Tanaka; Satoru Matono; Naoki Mori; Kazuo Shirouzu; Hideaki Yamana; Gen Suzuki; Naofumi Hayabuchi; Masasuke Matsui
Journal:  World J Surg       Date:  2005-01       Impact factor: 3.352

Review 2.  Chemoradiotherapy and surgery for T4 esophageal cancer in Japan.

Authors:  Yasunori Akutsu; Hisahiro Matsubara
Journal:  Surg Today       Date:  2015-01-13       Impact factor: 2.549

Review 3.  Surgical strategies for treatment of clinical T4 esophageal cancer in Japan.

Authors:  Kazuhiko Yamada; Kyoko Nohara; Naoki Enomoto; Hitomi Wake; Syusuke Yagi; Masayoshi Terayama; Daiki Kato; Chizu Yokoi; Yasushi Kojima; Hidetsugu Nakayama; Norihiro Kokudo
Journal:  Glob Health Med       Date:  2021-12-31

Review 4.  Current status of neoadjuvant therapy for adenocarcinoma of the distal esophagus.

Authors:  Johannes Zacherl; Andreas Sendler; Hubert J Stein; Katja Ott; Marcus Feith; Raimund Jakesz; J Rüdiger Siewert; Ulrich Fink
Journal:  World J Surg       Date:  2003-08-28       Impact factor: 3.352

Review 5.  Robotic esophagectomy.

Authors:  Brett Broussard; John Evans; Benjamin Wei; Robert Cerfolio
Journal:  J Vis Surg       Date:  2016-08-10

Review 6.  Secondary tracheal tumors: a systematic review.

Authors:  Maria Lucia Madariaga; Henning A Gaissert
Journal:  Ann Cardiothorac Surg       Date:  2018-03

Review 7.  Treatment and clinical outcome of clinical T4 esophageal cancer: A systematic review.

Authors:  Tomoki Makino; Makoto Yamasaki; Koji Tanaka; Yasuhiro Miyazaki; Tsuyoshi Takahashi; Yukinori Kurokawa; Masaaki Motoori; Yutaka Kimura; Kiyokazu Nakajima; Masaki Mori; Yuichiro Doki
Journal:  Ann Gastroenterol Surg       Date:  2018-12-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.